Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp188 | Cell biology: osteoblasts and bone formation | ECTS2013

Intracellular calcium fluxes in human bone cells in osteoporotic and osteoarthritic patients

celi Monica , Gasbarra Elena , Frank Claudio , Cutarelli Alessandro , Cinci Giulio Fioravanti , Tarantino Umberto

We studied changes in intracellular Ca2+ concentration in bone cell cultures obtained from human subjects with osteoporosis and osteoarthritis, to evaluate differences between these patients and healthy subjects. We enrolled 36 patients: 12 undergoing primary total hip arthroplasty for osteoporotic femoral fractures (group A, mean age range 57–80), 12 for hip osteoarthritis (group B, mean age range 57–80), and 12 healthy subjects who suffered a high-energy...

ba0001pp375 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

25-Hydroxyvitamin D values in liver transplant candidates

Monegal Ana , Peris Pilar , Cuervo Andrea , Muxi Africa , Gifre Laia , Guanabens Nuria

Introduction: Liver transplant candidates have bone and mineral metabolism disorders that may influence the development of fractures after liver transplantation (LT).Objective: To analyze the levels of 25-hydroxyvitamin D (25-OH-D) in patient candidates for LT and the factors associated with vitamin D deficiency.Methods: Between January 2010 and May 2012, 116 liver transplant candidates (85 male and 31 female patients) were include...

ba0005p413 | Osteoporosis: treatment | ECTS2016

Dose postoperative applications of diphosphonate medicine at an early stage have influence on union of fracture?

Li Qiang , Zhang Jia , Zhu Shen

Background: Surgical and conservative treatments are both crucial method to deal with osteoporotic fracture, anti-osteoporotic therapy is the most important among conservative treatments and diphosphonate medicine is the first-line choice. The pharmacological action of diphosphonate medicine is to inhibit the function of osteoclast, so there is no consensus if it will inhibit porosis and union of fracture.Purpose: To find out the influence of diphosphona...

ba0006oc26 | (1) | ICCBH2017

A randomized, open-label Phase 2 study of KRN23, an investigational fully human Anti-FGF23 monoclonal antibody, in children with X-linked Hypophosphatemia (XLH)

Hogler Wolfgang , Portale Anthony , Imel Erik , Boot Annemieke , Linglart Agnes , Padidela Raja , van't Hoff William , Whyte Michael , Mao Meng , Skrinar Alison , Martin Javier San , Carpenter Thomas

Objectives: In XLH, FGF23-mediated hypophosphatemia leads to defective bone mineralization and rickets. Investigational product KRN23 binds FGF23 and inhibits its activity. The objective of this Phase 2 study was to evaluate the safety and efficacy of KRN23 in 52 children with XLH (ages 5–12 years, ≤Tanner 2).Methods: Patients were randomized to receive KRN23 biweekly (Q2W) or monthly (Q4W) by SC injection. KRN23 dose was titrated (maximum 2 m...

ba0006lb3 | (1) | ICCBH2017

Mediating effect of muscle on the relationship of physical activity trajectories and bone outcomes: The Iowa Bone Development Study

Zymbal Vera , Baptista Fatima , Letuchy Elena M. , Janz Kathleen F.

Objectives: This study analysed prospective associations between two distinct developmental trajectories of objectively-measured physical activity and late adolescent bone parameters (age 17 yr) by exploring the mediating effects of lean soft tissue (LST), a surrogate of muscle mass.Methods: In approximately 349 participants (191 girls) of the Iowa Bone Development Study, physical activity was measured by accelerometry starting at age 5 and continuing at...

ba0004is15biog | (1) (1) | ICCBH2015

Achondroplasia-new therapy

Legeai-Mallet Laurence

Biographical DetailsLaurence Legeai-Mallet is currently Director of Research at Imagine Institute-Paris Descartes University. She received her PhD in genetic from University of Paris V, she is a member of International skeletal dysplasia Society, European Skeletal Dysplasia Network and the French reference center of bone dysplasias. She has been involved in the field of skeletal disease s...

ba0006oc23 | (1) | ICCBH2017

Sustained radiographic and functional improvements with asfotase alfa treatment from up to 7 years in children with hypophosphatasia

Whyte Michael P. , Rockman-Greenberg Cheryl , Moseley Scott , Denker Andrew E. , McAlister William H.

Objective: Children with hypophosphatasia (HPP) treated with asfotase alfa in a Phase 2 study (NCT00952484) and its open-label extension (NCT01203826) experienced significant improvements in skeletal mineralization and physical function that were sustained through 5 years of treatment (1). Herein, we report data from these studies with a maximum of 7 years of treatment.Methods: Children with HPP aged 6–12 years at baseline received asfotase alfa (3 ...

ba0007oc14 | (1) | ICCBH2019

Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia

Ward Leanne , Imel Erik , Whyte Michael , Munns Craig , Portale Anthony , Hogler Wolfgang , Simmons Jill , Padidela Raja , Namba Noriyuki , Cheong Hae , Nilsson Ola , Mao Meng , Skrinar Alison , Chen Chao-Yin , Martin Javier San , Glorieux Francis

Objective: We compared the efficacy and safety of burosumab, a monoclonal antibody against FGF23, to conventional therapy [oral phosphate and active vitamin D (Pi/D)] in children with X-linked hypophosphatemia (XLH).Methods: In this Phase 3 trial (NCT02915705), 61 children with XLH (1-12 years-old) were randomized 1:1 after a 7-day Pi/D washout to receive burosumab starting at 0.8 mg/kg SC Q2W or reinitiate Pi/D optimally titrated by investigators. Eligi...

ba0007p62 | (1) | ICCBH2019

Tissue non-specific alkaline phosphatase activity and mineralization capacity of bi-allelic mutations from severe perinatal and asymptomatic hypophosphatasia phenotypes: Results from an in-vitro mutagenesis model

Uday Suma , Matsumara Tomohiro , Saraff Vrinda , Saito Shiho , Orimo Hideo , Hogler Wolfgang

Introduction: Hypophosphatasia (HPP) characterized by reduced mineralization occurs from mutations in the tissue non-specific alkaline phosphatase (ALPL) gene. Individuals harbouring bi-allelic mutations are generally reported to be severely affected. We report the findings of in vitro functional studies following site-directed mutagenesis in bi-allelic mutations causing extreme clinical phenotypes; severe perinatal and asymptomatic HPP.Objectiv...

ba0001oc3.3 | Osteoporosis pathophysiology and genetics | ECTS2013

Distinct relationships of intramuscular and subcutaneous fat with cortical bone: findings from a cross sectional study of young adult males and females

Deere Kevin , Sayers Adrian , Viljakainen Heli , Lawlor Debbie , Sattar Naveed , Kemp John , Fraser William , Tobias Jon

Introduction: Intracellular fat within muscle and visceral tissue has been suggested to adversely influence bone development.Design: We aimed to compare associations between intramuscular and subcutaneous fat and cortical bone outcomes in young adults, in cross-sectional analyses based on the Avon Longitudinal Study of Parents and Children.Method: Data were collected from a research clinic conducted at 17 years of age. Intramuscula...